Article and Video CATEGORIES
GRACE has partnered with Clinical Care Options (CCO) Oncology, to share with our community a series of educational videos regarding Measurable Residual Disease (MRD) in acute lymphocytic leukemia (ALL).
We are thrilled to share with you video discussions with the following panel:
- ~Elias Jabbour, MD, Associate Professor Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston, Texas
- ~Joseph D. Khoury, MD, Professor, Department of Hematology at the University of Texas MD Anderson Cancer Center in Houston, Texas
- ~Aaron C. Logan, MD, Ph.D., Associate Professor Division of Hematology and Blood and Marrow Transplantation at the University of California, San Francisco
In this video series, the doctors discuss MRD in ALL. Topics include:
Measurable Residual Disease - What Can Physicians Do with MRD Information
Measurable Residual Disease - What Does it Mean to be MRD Positive
Measurable Residual Disease - What is MRD and Why is it Important
Measurable Residual Disease - What Tests Used, How do They Work, and Which is Best for the Patient
Measurable Residual Disease - When Should they Test MRD and How do they get MRD from Patients
For more information about this video program with CCO - please visit https://www.clinicaloptions.com/oncology/programs/mrd-in-all/on-demand-….
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…